Table 2. Daily estimation of serum levels of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1), tumour necrosis factor-alpha (TNFα), interleukin-6 (IL-6) and IL-8 of 90 patients with septic syndrome in the field of ventilator-associated pneumonia (VAP) in relation to the resolution or not of VAP.

	Resolution of VAP (n = 49)	VAP unresolved (n = 41)	P-value
sTREM-1 (pg/ml, median-range)
Day 1	79·8 (15·1–997·5)	131·8 (15·1–513·8)	0·049
Day 2	75·3 (15·1–1054·5)	172·8 (15·1–912·2)	0·025
Day 3	77·6 (15·1–1145·8)	125·1 (15·1–902·4)	0·040
Day 4	75·6 (15·1–975·6)	143·7 (23·4–642·2)	0·029
Day 5	94·1 (15·1–763·2)	182·9 (15·1–1269·5)	0·029
Day 6	91·5 (15·1–887·8)	163·3 (15·1–1630·5)	0·013
Day 7	87·9 (15·1–1041·2)	200·7 (15·1–978·1)	0·016
TNFα (pg/ml, median-range)
Day 1	5·61 (0·70–36·17)	6·36 (0·45–42·97)	NS*
Day 2	5·29 (0·42–37·05)	6·09 (1·52–84·45)	NS
Day 3	5·19 (0·42–490·39)	8·82 (1·32–178·57)	NS
Day 4	5·09 (0·39–25·94)	6·06 (1·15–609·03)	NS
Day 5	5·08 (0·84–31·89)	7·61 (3·20–381·08)	0·014
Day 6	5·36 (1·54–720·90)	10·16 (1·35–786·07)	0·014
Day 7	5·46 (1·60–27·66)	10·25 (1·63–1801·62)	0·026
IL-6 (pg/ml, median-range)
Day 1	89·25 (12·76–256·63)	147·00 (15·60–347·05)	0·022
Day 2	85·23 (< 6·25–244·60)	90·30 (12·86–312·72)	0·018
Day 3	83·29 (< 6·25–248·51)	143·42 (17·89–314·92)	0·001
Day 4	74·66 (< 6·25–240·19)	165·71 (12·63–325·35)	0·001
Day 5	54·72 (< 6·25–264·97)	128·18 (< 6·25–336·46)	0·007
Day 6	53·76 (< 62·5–219·23)	162·75 (13·23–364·97)	< 0·0001
Day 7	40·49 (< 6·25–198·83)	114·97 (20·82–326·49)	< 0·0001
IL-8 (pg/ml, median-range)
Day 1	72·6 (< 62·5–1439·4)	74·6 (< 62·5–1716·9)	NS
Day 2	< 62·5 (< 62·5–1540·0)	< 62·5 (< 62·5–1617·6)	NS
Day 3	142·5 (< 62·5–1623·4)	< 62·5 (< 62·5–16, 137·8)	NS
Day 4	134·3 (< 62·5–1767·1)	< 62·5 (< 62·5–1886·8)	NS
Day 5	133·5 (< 62·5–1560·1)	< 62·5 (< 62·5–1683·7)	NS
Day 6	86·1 (< 62·5–1540·0)	< 62·5 (< 62·5–2594·8)	NS
Day 7	108·0 (< 62·5–1686·6)	255·5 (< 62·5–3013·2)	0·049

^*NS: nonsignificant